Joe Breen, 38, is one of thousands of people whose experiences with GLP-1s such as Ozempic and Wegovy have radically changed their relationship with alcohol. Are these drugs the future for treating ...

One analysis of these same clinical trials reported the overall average weight loss on naltrexone/bupropion to be a little over 4% relative to placebo. Naltrexone treats drug and alcohol ...

The campaign inspires individuals to seek help in taking control of their weight-loss efforts with CONTRAVE, an established ...

the association with bupropion and naltrexone became statistically insignificant when adjusted for weight loss. Researchers hypothesized that certain pharmacological properties of obesity drugs ...

Weight loss medications typically suppress a person ... Contrave belongs to a class of drugs known as bupropion/naltrexone. Bupropion is a type of antidepressant, whereas naltrexone is an ...

He was also taking three blood pressure medications ... common forms of GLP-1s used for weight loss are subcutaneous injections given once a week. “Naltrexone has a half-life of 5 hours ...

Encouraged by her weight-loss progress, Breen decided to give another member of this class of drugs, known as GLP-1 agonists, a shot. Eight months after he stopped taking naltrexone, in April 2023 ...

Anti-obesity medication use was associated with reduced alcohol consumption among patients in a telehealth medical weight ...

Currax Pharmaceuticals is taking a page out of Lesley Gore’s playbook to remind patients that obesity doesn’t own them. The drugmaker launched a campaign supporting its weight loss medication ...

The weight loss medications on the market today are generally ... by 5.4 percent with liraglutide (Saxenda), 4 percent with naltrexone-bupropion (Contrave), and 2.9 percent with orlistat (Xenical).